Intervention not reported
Neuropathy (grade 3/4) · women with newly diagnosed EOC (stage Ic to IV)
The intervention leads to lower neuropathy (grade 3/4) (high certainty).
1 finding from 1 review
Death from all causes · women with stage I endometrial cancer
Summary of findings: EBRT showed no clear difference in death from all causes compared with no EBRT (moderate certainty).
1 finding from 1 review
HR 0.99 [0.82, 1.2]
2628 participants
Moderate
Endometrial carcinoma‐related death · women with stage I endometrial cancer
Summary of findings: EBRT showed no clear difference in endometrial carcinoma‐related death compared with no EBRT (moderate certainty).
1 finding from 1 review
HR 0.96 [0.72, 1.28]
2965 participants
Moderate
Locoregional recurrence · women with stage I endometrial cancer
Summary of findings: EBRT leads to lower locoregional recurrence compared with no EBRT (high certainty).
1 finding from 1 review
HR 0.36 [0.25, 0.52]
2965 participants
High
Severe acute toxicity · women with stage I endometrial cancer
Summary of findings: EBRT leads to higher severe acute toxicity compared with no EBRT (high certainty).
1 finding from 1 review
RR 4.68 [1.35, 16.16]
1328 participants
High
Severe late toxicity · women with stage I endometrial cancer
Summary of findings: EBRT leads to higher severe late toxicity compared with no EBRT (high certainty).
1 finding from 1 review
RR 2.58 [1.61, 4.11]
3501 participants
High
All cause mortality · patients with afebrile neutropenia induced by chemotherapy
Summary of findings: antibiotics leads to lower all cause mortality compared with placebo or no intervention (high certainty).
1 finding from 1 review
Febrile patients and episodes · patients with afebrile neutropenia induced by chemotherapy
Summary of findings: antibiotics probably leads to lower febrile patients and episodes compared with placebo or no intervention (moderate certainty).
1 finding from 1 review
Bacteraemia · patients with afebrile neutropenia induced by chemotherapy
Summary of findings: antibiotics leads to lower bacteraemia compared with placebo or no intervention (high certainty).
1 finding from 1 review
All cause‐mortality · cancer patients with afebrile neutropenia following chemotherapy
Summary of findings: quinolone prophylaxis probably leads to higher all cause‐mortality compared with TMP‐SMZ prophylaxis (moderate certainty).
1 finding from 1 review
Febrile patients and episodes · cancer patients with afebrile neutropenia following chemotherapy
Summary of findings: quinolone prophylaxis probably leads to lower febrile patients and episodes compared with TMP‐SMZ prophylaxis (moderate certainty).
1 finding from 1 review
Bacteraemia · cancer patients with afebrile neutropenia following chemotherapy
Summary of findings: quinolone prophylaxis probably leads to lower bacteraemia compared with TMP‐SMZ prophylaxis (moderate certainty).
1 finding from 1 review
Intervention not reported
Overall quality of life change score ‐ up to 12 weeks' · Cancer survivors who have completed active cancer treatment
1 finding from 1 review
Intervention not reported
Overall social functioning change ‐ up to 12 weeks' · Cancer survivors who have completed active cancer treatment
1 finding from 1 review
Intervention not reported
Overall social functioning change ‐ 6 months' · Cancer survivors who have completed active cancer treatment
1 finding from 1 review
Intervention not reported
Overall quality of life change score ‐ 6 months' · Cancer survivors who have completed active cancer treatment
1 finding from 1 review
Intervention not reported
Overall anxiety change ‐ Up to 12 weeks' · Cancer survivors who have completed active cancer treatment
1 finding from 1 review
Intervention not reported
Overall emotional well‐being/mental health change ‐ up to 12 weeks' · Cancer survivors who have completed active cancer treatment
1 finding from 1 review
Intervention not reported
Overall fatigue change ‐ Up to 12 weeks' · Cancer survivors who have completed active cancer treatment
1 finding from 1 review
Intervention not reported
Overall fatigue change ‐ More than 12 weeks less than 6 months' · Cancer survivors who have completed active cancer treatment
1 finding from 1 review